US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

FibroBiologics

0.2480

-0.0032-1.27%

Post-market: 0.2450-0.0030-1.21%17:52 EST

Volume:217.24K

Turnover:56.14K

Market Cap:16.50M

PE:-0.51

High:0.2675

Open:0.2500

Low:0.2480

Close:0.2512

52wk High:1.53

52wk Low:0.2201

Shares:66.52M

Float Shares:56.56M

Volume Ratio:0.57

T/O Rate:0.38%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4850

EPS(LYR):-0.3395

ROE:-1292.87%

ROA:-115.62%

PB:131.98

PE(LYR):-0.73

Loading ...

Overview Company News Filings

FibroBiologics CEO Pete O’Heeron to Speak at A4LI’s H-SPAN Summit at Georgetown University

FibroBiologics Faces Nasdaq Delisting Review After Noncompliance

FibroBiologics droht Nasdaq-Delisting wegen Nichteinhaltung von Börsenauflagen

FibroBiologics erhält kanadisches Patent für neuartige Cachexie-Therapie

Fibrobiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

THOMSON REUTERS

FibroBiologics CEO to Present at DealFlow Discovery Conference

FibroBiologics Is Maintained at Buy by D. Boral Capital

FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference

BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy

FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease

Fibrobiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-Derived Chondrocyte (Fsdc) Spheroid Therapy for Degenerative Disc Disease

THOMSON REUTERS

Nasdaq Threatens Delisting of Fibrobiologics Inc. Over Prolonged Low Share Price

FibroBiologics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

FibroBiologics Files IND Application with FDA for Psoriasis Therapy

Fibrobiologics Files Ind Application With the U.S. FDA to Advance Clinical Development of Cyps317 in Patients With Psoriasis

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FBLG/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FBLG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.248,"timestamp":1771621200000,"preClose":0.2512,"halted":0,"volume":217238,"hourTrading":{"tag":"盘后","latestPrice":0.245,"preClose":0.248,"latestTime":"17:52 EST","volume":4476,"amount":1161.7756,"timestamp":1771627933541,"change":-0.003,"changeRate":-0.012097,"amplitude":0.108065},"delay":0,"changeRate":-0.012738853503184638,"floatShares":56556500,"shares":66519700,"eps":-0.484982,"marketStatus":"Market Closed","change":-0.0032,"latestTime":"02-20 16:00:00 EST","open":0.25,"high":0.2675,"low":0.248,"amount":56135.30718432,"amplitude":0.077627,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.484982,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.2512,"preHourTrading":{"tag":"盘前","latestPrice":0.263,"preClose":0.2512,"latestTime":"09:26 EST","volume":9056,"amount":2381.0312313599998,"timestamp":1771597592782,"change":0.0118,"changeRate":0.046975,"amplitude":0.114252},"postHourTrading":{"tag":"盘后","latestPrice":0.245,"preClose":0.248,"latestTime":"17:52 EST","volume":4476,"amount":1161.7756,"timestamp":1771627933541,"change":-0.003,"changeRate":-0.012097,"amplitude":0.108065},"volumeRatio":0.572051824757397},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBLG\",,,,,undefined,":{"symbol":"FBLG","floatShares":56556500,"roa":"-115.62%","roe":"-1292.87%","lyrEps":-0.339497,"volumeRatio":0.572051824757397,"shares":66519700,"dividePrice":0,"high":0.2675,"amplitude":0.077627,"preClose":0.2512,"low":0.248,"week52Low":0.2201,"pbRate":"131.98","week52High":1.53,"institutionHeld":0,"latestPrice":0.248,"eps":-0.484982,"divideRate":0,"volume":217238,"delay":0,"ttmEps":-0.484982,"open":0.25,"prevYearClose":0.2249,"prevWeekClose":0.251,"prevMonthClose":0.3318,"prevQuarterClose":0.2249,"fiveDayClose":0.246,"twentyDayClose":0.34,"sixtyDayClose":0.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBLG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"FBLG","fiscalQuarterEnding":"2025/09","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761883200000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-07-31","symbol":"FBLG","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1753934400000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBLG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBLG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1730264400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FBLG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FBLG","date":"2026-02-20","current":-0.511359,"percent":0.943434,"low":-68.573467,"twenty":-7.769521,"median":-3.544415,"eighty":-1.692292,"high":-0.723127,"avg":-7.253918,"sd":10.290516,"marketCap":16709754},"quantilePoints":[{"date":"2024-02-02","current":-68.573467,"twenty":-68.573467,"median":-68.573467,"eighty":-68.573467,"marketCap":568611190},{"date":"2024-02-09","current":-30.642544,"twenty":-58.777258,"median":-48.452053,"eighty":-34.01244,"marketCap":254087971},{"date":"2024-02-16","current":-50.313332,"twenty":-58.777258,"median":-50.313332,"eighty":-30.642544,"marketCap":417198153},{"date":"2024-02-23","current":-47.413654,"twenty":-56.896385,"median":-48.5892,"eighty":-33.338461,"marketCap":393154022},{"date":"2024-03-01","current":-25.741365,"twenty":-54.984165,"median":-48.491237,"eighty":-33.338461,"marketCap":424346408},{"date":"2024-03-08","current":-19.47356,"twenty":-53.244359,"median":-47.492024,"eighty":-25.717713,"marketCap":321021631},{"date":"2024-03-15","current":-20.892685,"twenty":-51.363486,"median":-37.245189,"eighty":-20.955758,"marketCap":344415920},{"date":"2024-03-22","current":-23.849198,"twenty":-50.446561,"median":-28.99678,"eighty":-20.813845,"marketCap":393154022},{"date":"2024-03-28","current":-23.159345,"twenty":-50.219289,"median":-25.741365,"eighty":-20.93999,"marketCap":381781799},{"date":"2024-04-05","current":-22.469492,"twenty":-49.216157,"median":-24.637601,"eighty":-21.160743,"marketCap":370409575},{"date":"2024-04-12","current":-22.311811,"twenty":-48.471645,"median":-23.652097,"eighty":-21.298713,"marketCap":367810209},{"date":"2024-04-19","current":-21.700799,"twenty":-48.064123,"median":-23.20862,"eighty":-21.030656,"marketCap":357737668},{"date":"2024-04-26","current":-23.021374,"twenty":-47.63309,"median":-22.804563,"eighty":-21.030656,"marketCap":379507354},{"date":"2024-05-03","current":-13.245174,"twenty":-47.445002,"median":-22.479347,"eighty":-20.675875,"marketCap":218346696},{"date":"2024-05-10","current":-17.22661,"twenty":-43.252224,"median":-22.05558,"eighty":-19.871704,"marketCap":283980674},{"date":"2024-05-17","current":-17.017594,"twenty":-36.598639,"median":-21.769784,"eighty":-19.221271,"marketCap":383406402},{"date":"2024-05-24","current":-16.310932,"twenty":-31.990502,"median":-21.661379,"eighty":-18.255477,"marketCap":367485289},{"date":"2024-05-31","current":-17.767522,"twenty":-29.984238,"median":-21.543118,"eighty":-17.827098,"marketCap":400302277},{"date":"2024-06-07","current":-14.972667,"twenty":-28.19741,"median":-21.306597,"eighty":-17.252609,"marketCap":337334178},{"date":"2024-06-14","current":-10.427133,"twenty":-26.746956,"median":-21.178482,"eighty":-16.659936,"marketCap":234923317},{"date":"2024-06-21","current":-7.769521,"twenty":-25.741365,"median":-20.932105,"eighty":-16.368618,"marketCap":175047318},{"date":"2024-06-28","current":-6.767471,"twenty":-25.694061,"median":-20.88283,"eighty":-16.302279,"marketCap":152471122},{"date":"2024-07-05","current":-6.143005,"twenty":-25.43783,"median":-20.64631,"eighty":-15.81876,"marketCap":138401898},{"date":"2024-07-12","current":-7.689204,"twenty":-24.673079,"median":-20.183123,"eighty":-14.136173,"marketCap":173237756},{"date":"2024-07-15","current":-7.514809,"twenty":-24.649427,"median":-20.094427,"eighty":-13.517924,"marketCap":169308652},{"date":"2024-08-02","current":-7.974576,"twenty":-24.625775,"median":-20.005732,"eighty":-13.175194,"marketCap":179667198},{"date":"2024-08-09","current":-4.080921,"twenty":-24.140907,"median":-19.700225,"eighty":-10.836667,"marketCap":79459622},{"date":"2024-08-16","current":-2.166861,"twenty":-23.730937,"median":-18.842837,"eighty":-9.439605,"marketCap":42190950},{"date":"2024-08-23","current":-2.546062,"twenty":-23.640271,"median":-18.638558,"eighty":-7.79743,"marketCap":49574366},{"date":"2024-08-30","current":-2.915474,"twenty":-23.407692,"median":-18.172694,"eighty":-7.552859,"marketCap":56767191},{"date":"2024-09-06","current":-3.368187,"twenty":-23.218475,"median":-17.767522,"eighty":-6.924314,"marketCap":65581972},{"date":"2024-09-13","current":-5.722296,"twenty":-23.104157,"median":-17.428613,"eighty":-6.143005,"marketCap":111418835},{"date":"2024-09-20","current":-5.722296,"twenty":-22.93465,"median":-17.22661,"eighty":-5.90745,"marketCap":111418835},{"date":"2024-09-27","current":-5.686079,"twenty":-22.765143,"median":-16.563311,"eighty":-5.873037,"marketCap":110713652},{"date":"2024-10-04","current":-4.798761,"twenty":-22.619289,"median":-16.368618,"eighty":-5.722296,"marketCap":93436681},{"date":"2024-10-11","current":-4.20118,"twenty":-22.481318,"median":-16.080185,"eighty":-5.265962,"marketCap":81801170},{"date":"2024-10-18","current":-6.012033,"twenty":-22.40642,"median":-15.807485,"eighty":-5.066768,"marketCap":117060295},{"date":"2024-10-25","current":-5.215258,"twenty":-22.209319,"median":-15.237992,"eighty":-5.131958,"marketCap":101546280},{"date":"2024-10-31","current":-5.342017,"twenty":-22.020102,"median":-13.586112,"eighty":-5.110228,"marketCap":104014418},{"date":"2024-11-08","current":-6.464746,"twenty":-21.866364,"median":-12.649071,"eighty":-5.128337,"marketCap":125875076},{"date":"2024-11-15","current":-5.477931,"twenty":-21.799349,"median":-10.768411,"eighty":-5.146445,"marketCap":97392141},{"date":"2024-11-22","current":-4.698155,"twenty":-21.716567,"median":-9.773622,"eighty":-5.018763,"marketCap":83528491},{"date":"2024-11-29","current":-5.107537,"twenty":-21.700799,"median":-9.003931,"eighty":-5.016064,"marketCap":90806907},{"date":"2024-12-06","current":-4.639671,"twenty":-21.661379,"median":-7.895306,"eighty":-4.997955,"marketCap":82488717},{"date":"2024-12-13","current":-4.425233,"twenty":-21.562828,"median":-7.720912,"eighty":-4.979847,"marketCap":78676213},{"date":"2024-12-20","current":-3.957367,"twenty":-21.543118,"median":-7.546517,"eighty":-4.853087,"marketCap":70358023},{"date":"2024-12-27","current":-4.50321,"twenty":-21.511582,"median":-7.203145,"eighty":-4.778145,"marketCap":80062578},{"date":"2025-01-03","current":-3.869642,"twenty":-21.385437,"median":-6.905845,"eighty":-4.698155,"marketCap":68798363},{"date":"2025-01-10","current":-4.065278,"twenty":-21.306597,"median":-6.609614,"eighty":-4.652603,"marketCap":72276579},{"date":"2025-01-17","current":-3.769263,"twenty":-21.298713,"median":-6.286711,"eighty":-4.50321,"marketCap":67013721},{"date":"2025-01-24","current":-3.157497,"twenty":-21.243525,"median":-6.193118,"eighty":-4.433031,"marketCap":56137148},{"date":"2025-01-31","current":-3.295638,"twenty":-21.050366,"median":-6.140899,"eighty":-4.36675,"marketCap":58593149},{"date":"2025-02-07","current":-3.157497,"twenty":-20.955758,"median":-6.004281,"eighty":-4.203103,"marketCap":56137148},{"date":"2025-02-14","current":-2.545732,"twenty":-20.888743,"median":-5.948653,"eighty":-4.068407,"marketCap":45260576},{"date":"2025-02-21","current":-2.447061,"twenty":-20.872975,"median":-5.908467,"eighty":-3.946872,"marketCap":43506290},{"date":"2025-02-28","current":-2.348389,"twenty":-20.794135,"median":-5.885273,"eighty":-3.784683,"marketCap":41752004},{"date":"2025-03-07","current":-2.210248,"twenty":-20.498484,"median":-5.867165,"eighty":-3.670591,"marketCap":39296004},{"date":"2025-03-14","current":-2.109947,"twenty":-20.183123,"median":-5.776622,"eighty":-3.453513,"marketCap":37512750},{"date":"2025-03-21","current":-2.151728,"twenty":-20.183123,"median":-5.722296,"eighty":-3.368187,"marketCap":38255577},{"date":"2025-03-28","current":-2.130838,"twenty":-20.005732,"median":-5.595537,"eighty":-3.295638,"marketCap":37884163},{"date":"2025-04-04","current":-2.958372,"twenty":-19.926892,"median":-5.518575,"eighty":-3.165965,"marketCap":33018387},{"date":"2025-04-11","current":-2.748074,"twenty":-19.788921,"median":-5.342017,"eighty":-3.105834,"marketCap":30671251},{"date":"2025-04-17","current":-3.685286,"twenty":-19.647008,"median":-5.282987,"eighty":-3.104326,"marketCap":41131477},{"date":"2025-04-25","current":-4.361485,"twenty":-19.501154,"median":-5.215258,"eighty":-3.131377,"marketCap":48678537},{"date":"2025-05-02","current":-3.496805,"twenty":-18.968982,"median":-5.142823,"eighty":-3.15355,"marketCap":39027837},{"date":"2025-05-09","current":-2.900977,"twenty":-18.732461,"median":-5.107537,"eighty":-3.105179,"marketCap":32377800},{"date":"2025-05-16","current":-5.090366,"twenty":-18.693381,"median":-5.090366,"eighty":-3.095239,"marketCap":39027837},{"date":"2025-05-23","current":-4.291877,"twenty":-18.607387,"median":-5.049055,"eighty":-3.101704,"marketCap":32905823},{"date":"2025-05-30","current":-3.742916,"twenty":-18.421041,"median":-5.00701,"eighty":-3.104523,"marketCap":28696939},{"date":"2025-06-06","current":-4.262932,"twenty":-18.227882,"median":-4.979847,"eighty":-3.124991,"marketCap":32683900},{"date":"2025-06-13","current":-4.354259,"twenty":-18.018955,"median":-4.934576,"eighty":-3.149603,"marketCap":33384106},{"date":"2025-06-20","current":-3.674878,"twenty":-17.856887,"median":-4.868731,"eighty":-3.157497,"marketCap":28175292},{"date":"2025-06-27","current":-3.644169,"twenty":-17.748258,"median":-4.815121,"eighty":-3.160884,"marketCap":27939844},{"date":"2025-07-03","current":-3.132347,"twenty":-17.688614,"median":-4.795627,"eighty":-3.157497,"marketCap":24015708},{"date":"2025-07-11","current":-3.321721,"twenty":-17.510817,"median":-4.711647,"eighty":-3.13343,"marketCap":25467638},{"date":"2025-07-18","current":-3.531568,"twenty":-17.278608,"median":-4.698155,"eighty":-3.14171,"marketCap":27076534},{"date":"2025-07-25","current":-3.36062,"twenty":-17.22661,"median":-4.675331,"eighty":-3.157497,"marketCap":25765873},{"date":"2025-08-01","current":-3.260303,"twenty":-17.184807,"median":-4.665775,"eighty":-3.157497,"marketCap":24996742},{"date":"2025-08-08","current":-1.692292,"twenty":-16.92818,"median":-4.639671,"eighty":-3.111465,"marketCap":22377179},{"date":"2025-08-15","current":-1.862725,"twenty":-16.567638,"median":-4.558872,"eighty":-3.098103,"marketCap":24630815},{"date":"2025-08-22","current":-1.865576,"twenty":-16.533025,"median":-4.524553,"eighty":-3.074912,"marketCap":24668515},{"date":"2025-08-29","current":-1.964732,"twenty":-16.426305,"median":-4.50321,"eighty":-3.015849,"marketCap":25979645},{"date":"2025-09-05","current":-1.881416,"twenty":-16.368618,"median":-4.425233,"eighty":-2.962429,"marketCap":24877961},{"date":"2025-09-12","current":-1.789547,"twenty":-16.310932,"median":-4.376497,"eighty":-2.933582,"marketCap":23663176},{"date":"2025-09-19","current":-1.694826,"twenty":-16.29651,"median":-4.361485,"eighty":-2.897365,"marketCap":22410690},{"date":"2025-09-26","current":-1.709716,"twenty":-15.863859,"median":-4.348021,"eighty":-2.853034,"marketCap":22607569},{"date":"2025-10-03","current":-1.710666,"twenty":-15.863859,"median":-4.327761,"eighty":-2.748074,"marketCap":22620136},{"date":"2025-10-10","current":-1.544034,"twenty":-15.807485,"median":-4.261494,"eighty":-2.486529,"marketCap":20416767},{"date":"2025-10-17","current":-1.298839,"twenty":-15.630094,"median":-4.210794,"eighty":-2.348389,"marketCap":17174548},{"date":"2025-10-24","current":-1.301056,"twenty":-15.503317,"median":-4.186877,"eighty":-2.318853,"marketCap":17203870},{"date":"2025-10-31","current":-1.257339,"twenty":-14.972667,"median":-4.132817,"eighty":-2.297962,"marketCap":16625800},{"date":"2025-11-07","current":-0.932278,"twenty":-13.927049,"median":-4.072247,"eighty":-2.249717,"marketCap":17248077},{"date":"2025-11-14","current":-0.933669,"twenty":-13.245174,"median":-4.04235,"eighty":-2.172619,"marketCap":17273805},{"date":"2025-11-21","current":-0.902797,"twenty":-13.070223,"median":-4.004863,"eighty":-2.130838,"marketCap":16702642},{"date":"2025-11-28","current":-0.907742,"twenty":-12.733301,"median":-3.95212,"eighty":-2.105769,"marketCap":16794130},{"date":"2025-12-05","current":-0.861361,"twenty":-11.417566,"median":-3.918378,"eighty":-2.038689,"marketCap":15936036},{"date":"2025-12-12","current":-1.151904,"twenty":-11.10969,"median":-3.880347,"eighty":-1.962831,"marketCap":21311383},{"date":"2025-12-19","current":-0.864342,"twenty":-10.563644,"median":-3.855551,"eighty":-1.925449,"marketCap":15991199},{"date":"2025-12-26","current":-0.781519,"twenty":-10.366139,"median":-3.817676,"eighty":-1.905048,"marketCap":14458888},{"date":"2026-01-02","current":-0.80862,"twenty":-10.104734,"median":-3.784683,"eighty":-1.867667,"marketCap":14960285},{"date":"2026-01-09","current":-1.186504,"twenty":-9.756195,"median":-3.726488,"eighty":-1.863485,"marketCap":21951508},{"date":"2026-01-16","current":-1.21347,"twenty":-9.439605,"median":-3.689721,"eighty":-1.817994,"marketCap":22450406},{"date":"2026-01-23","current":-1.222459,"twenty":-8.832939,"median":-3.685286,"eighty":-1.804182,"marketCap":22616705},{"date":"2026-01-30","current":-1.226773,"twenty":-8.114091,"median":-3.670176,"eighty":-1.745069,"marketCap":22696529},{"date":"2026-02-06","current":-0.81653,"twenty":-7.942868,"median":-3.64061,"eighty":-1.71998,"marketCap":15106628},{"date":"2026-02-13","current":-0.884485,"twenty":-7.806733,"median":-3.5628,"eighty":-1.705851,"marketCap":16363851},{"date":"2026-02-20","current":-0.903181,"twenty":-7.769521,"median":-3.544415,"eighty":-1.692292,"marketCap":16709754}],"updateTime":1771711953556},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBLG\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610625857","title":"FibroBiologics CEO Pete O’Heeron to Speak at A4LI’s H-SPAN Summit at Georgetown University","url":"https://stock-news.laohu8.com/highlight/detail?id=2610625857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610625857?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:47","pubTimestamp":1770731259,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. Chairman and CEO Pete O’Heeron has been selected as a main stage speaker at the upcoming A4LI’s H-SPAN Summit at Georgetown University. The event, hosted by the Alliance for Longevity Initiatives, has become a prominent forum for shaping America’s longevity policy agenda. For more information on A4LI’s H-SPAN Summit at Georgetown University or to register, visit: https://a4li.org/h-span-summit-dc/. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLcbNjTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2609143405","title":"FibroBiologics Faces Nasdaq Delisting Review After Noncompliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609143405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609143405?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:33","pubTimestamp":1770413638,"startTime":"0","endTime":"0","summary":"FibroBiologics, Inc. ( ($FBLG) ) has issued an update. On August 4, 2025, FibroBiologics, Inc. was notified by Nasdaq that its market value of list...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-faces-nasdaq-delisting-review-after-noncompliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrobiologics-faces-nasdaq-delisting-review-after-noncompliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBLG","NQmain","BK4139"],"gpt_icon":0},{"id":"2609511524","title":"FibroBiologics droht Nasdaq-Delisting wegen Nichteinhaltung von Börsenauflagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2609511524","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609511524?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:10","pubTimestamp":1770412259,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLn2xTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2609303106","title":"FibroBiologics erhält kanadisches Patent für neuartige Cachexie-Therapie","url":"https://stock-news.laohu8.com/highlight/detail?id=2609303106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609303106?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298231,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8fQdKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","FBLG","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4139","BK4112","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2609173303","title":"Fibrobiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia","url":"https://stock-news.laohu8.com/highlight/detail?id=2609173303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609173303?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:30","pubTimestamp":1770298203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nTUA8RC2CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2604115783","title":"FibroBiologics CEO to Present at DealFlow Discovery Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115783","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115783?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:30","pubTimestamp":1768915824,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the DealFlow Discovery Conference on January 29, 2026, at the Borgata in Atlantic City, New Jersey. Founder and CEO Pete O'Heeron is scheduled to deliver the company presentation at 11:30 a.m. ET, and the company will also be available for one-on-one investor meetings throughout the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL1C63ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4588","FBLG","LU2210150020.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","BK4585","BK4139","LU2095319765.USD","SG9999014039.USD","NDAQ"],"gpt_icon":0},{"id":"2601151818","title":"FibroBiologics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601151818","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601151818?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:51","pubTimestamp":1767711060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 09:51 ET (14:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2601890613","title":"FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890613","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601890613?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:30","pubTimestamp":1767706221,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc., a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast technology, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference. The presentation is scheduled for 4:30 p.m. PT on Sunday, January 11, 2026, at The St. Regis in San Francisco, California.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL2PV6Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","FBLG","BK4588","SG9999014005.SGD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014021.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2601807668","title":"BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601807668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601807668?lang=en_us&edition=fundamental","pubTime":"2026-01-05 23:05","pubTimestamp":1767625533,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrobiologics Announces Results For Fibroblast Spheroid-Derived Chondrocyte Spheroid Therapy Jan 5 (Reuters) - Fibrobiologics Inc FBLG.O:FIBROBIOLOGICS ANNOUNCES POSITIVE PRECLINICAL RESULTS FO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA6NC05P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2601884339","title":"FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884339","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884339?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619818,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has announced positive preclinical results for its investigational FSdC spheroid-based therapy, designed to treat degenerative disc disease. The data showed that FSdC spheroids led to statistically significant and superior improvements in disc preservation and structural integrity compared to other treatments in animal models. These findings support the therapy’s potential regenerative effects, including enhanced extracellular matrix remodeling and inflammation control. The results have been announced by the company but have not yet been presented at a scientific meeting. FibroBiologics plans to advance FSdC into clinical development in collaboration with regulatory authorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbqB9YX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU0314104364.USD","FBLG","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","NDAQ","IE00B64PRP62.GBP","BK4588"],"gpt_icon":0},{"id":"2601881096","title":"Fibrobiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-Derived Chondrocyte (Fsdc) Spheroid Therapy for Degenerative Disc Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881096?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:30","pubTimestamp":1767619802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA6NC05P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2600095314","title":"Nasdaq Threatens Delisting of Fibrobiologics Inc. Over Prolonged Low Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095314","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095314?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:15","pubTimestamp":1767392157,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. is facing potential delisting from the Nasdaq Capital Market after its common stock price remained below the required $1.00 minimum bid for 30 consecutive trading days, violating Nasdaq Listing Rule 5550. The company received a notice from Nasdaq and was given 180 days, until December 29, 2025, to regain compliance. After failing to do so, FibroBiologics received a second notice indicating that Nasdaq staff intends to delist its securities, although a hearing request by the company will temporarily halt any delisting actions. To address the issue, the company has proposed a reverse stock split, subject to shareholder approval, but there is no guarantee these efforts will succeed or that an extension will be granted.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL5VKz8t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2600851068","title":"FibroBiologics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2600851068","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600851068?lang=en_us&edition=fundamental","pubTime":"2026-01-02 19:22","pubTimestamp":1767352920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FBLG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2026 06:22 ET (11:22 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG"],"gpt_icon":0},{"id":"2595774674","title":"FibroBiologics Files IND Application with FDA for Psoriasis Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595774674","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595774674?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:30","pubTimestamp":1767187810,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc. has filed a Phase 1/2 Investigational New Drug  application with the U.S. Food and Drug Administration  to advance clinical development of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. The IND submission seeks regulatory clearance to initiate first-in-human clinical trials and includes comprehensive preclinical pharmacology, safety, and manufacturing data. This filing marks a significant step in the company's efforts to develop innovative therapies for chronic inflammatory diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire  on Decemb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL3sPytr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","FBLG","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2595621774","title":"Fibrobiologics Files Ind Application With the U.S. FDA to Advance Clinical Development of Cyps317 in Patients With Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2595621774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595621774?lang=en_us&edition=fundamental","pubTime":"2025-12-31 21:30","pubTimestamp":1767187808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y101V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2593510240","title":"U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510240?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:49","pubTimestamp":1766389793,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Comerica, Heico, WalmartDec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comerica, Heico and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMA","IE00B19Z8X17.USD","AXP","APRE","CUBE","AFL","CCL","CFG","CNTX","CYTK","COF","LU1951200564.SGD","FBLG","DKNG","FOLD","LEU","FISV","GOOGL","GAP","CAG","LU1116320737.USD","BOW","FRT","BK4516","ASB","AZZ","BMBL","FLUT","LU2242649171.HKD","T","AIG","LU0323591593.USD","LU2275660780.HKD","ALZN","ANF","CWAN","HEI","DRI","CINF","FITB","LU0052756011.USD","BKSY","LU0187121727.USD","CRSR","AKTX","ALLY","ELF","EOSE","LU0689472784.USD","BMRN"],"gpt_icon":1},{"id":"2591649631","title":"Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591649631?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUABXDLM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2591499596","title":"Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2591499596","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591499596?lang=en_us&edition=fundamental","pubTime":"2025-12-15 21:00","pubTimestamp":1765803600,"startTime":"0","endTime":"0","summary":"HOUSTON, Dec. 15, 2025  -- FibroBiologics, Inc.  , a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of its common stock at an offering price of $0.33 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to an aggregate of 5,227,275 shares of common stock at an exercise price of $0.33 per share. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the Company's stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants  and will expire five years followi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","FBLG","BK4139"],"gpt_icon":0},{"id":"2590505734","title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505734","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505734?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:16","pubTimestamp":1765541802,"startTime":"0","endTime":"0","summary":"Ruben A. Garcia, General Counsel of Fibrobiologics Inc., has reported the acquisition of common shares of the company, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL8NqByT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2590580765","title":"FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580765?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373400,"startTime":"0","endTime":"0","summary":"Platform Poised to Expand into Joint and Cartilage RepairHOUSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechn","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203156/0/en/FibroBiologics-Files-Patent-Application-Covering-Novel-Fibroblast-Based-Chondrocyte-Spheroid-Platform-for-Orthopedic-and-Musculoskeletal-Conditions.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}